Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Published in: New England Journal of Medicine
Access to document
10.1056/NEJMoa2301665
document
Background: In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those who received standard care. Data were needed on longer-term outcomes. Methods: In this trial, we randomly assigned patients with early relapsed or refractory large B-cell lymphoma in a 1:1 ratio to receive either axi-cel or standard care (two to three cycles of chemoimmunotherapy...
ZUMA-7 Investigators and Kite Member, Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, David B. Miklos, Miguel Angel Perales, Armin Ghobadi, Aaron P. Rapoport, Anna Sureda, Caron A. Jacobson, Umar Farooq, Tom Van Meerten, Matthew Ulrickson, Mahmoud Elsawy, Lori A. Leslie, Sridhar Chaganti, Michael Dickinson, Kathleen Dorritie, Patrick M. Reagan, Joseph McguirkKevin W. Song, Peter A. Riedell, Monique C. Minnema, Yin Yang, Saran Vardhanabhuti, Simone Filosto, Paul Cheng, Shilpa A. Shahani, Marco Schupp, Christina To, Frederick L. Locke
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study
Published in: EClinicalMedicine
Access to document
10.1016/j.eclinm.2023.102040
document
Background: Patients with haematological malignancies have impaired antibody responses to SARS-CoV-2 vaccination. We aimed to investigate whether a fourth mRNA COVID-19 vaccination improved antibody quantity and quality. Methods: In this cohort study, conducted at 5 sites in the Netherlands, we compared antibody concentrations 28 days after 4 mRNA vaccinations (3-dose primary series plus 1 booster vaccination) in SARS-CoV-2 naive, immunocompromised patients with haematological malignancies to those obtained by age-matched, healthy individuals who had received the standard primary 2-dose mRNA vaccination schedule followed by a first booster mRNA vaccination....
COBRA KAI study team, Quincy Hofsink, Sabine Haggenburg, Birgit I. Lissenberg-Witte, Annoek E.C. Broers, Jaap A. van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J.E. Haverkate, Johan van Meerloo, Judith A. Burger, Joey H. Bouhuijs, Gaby P. Smits, Dorine Wouters, Ester M.M. van Leeuwen, Hetty J. Bontkes, Neeltje A. Kootstra, Sandra Vogels-Nooijen, Nynke Y. RotsJosine van Beek, Mirjam H.M. Heemskerk, Kazimierz Groen, Tom van Meerten, Pim G.N.J. Mutsaers, Marit J. van Gils, Abraham Goorhuis, Caroline E. Rutten, Mette D. Hazenberg, Inger S. Nijhof, Margriet J. Dijkstra
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Published in: -
Access to document
10.1182/bloodadvances.2022009578
document
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the...
Jaap A. van Doesum, Jon Salmanton-García, Francesco Marchesi, Roberta Di Blasi, Iker Falces-Romero, Alba Cabirta, Francesca Farina, Caroline Besson, Barbora Weinbergerová, Jens Van Praet, Martin Schönlein, Alberto López-García, Sylvain Lamure, Anna Guidetti, Cristina De Ramón-Sánchez, Josip Batinić, Eleni Gavriilaki, Athanasios Tragiannidis, Maria Chiara Tisi, Gaëtan PlantefeveVerena Petzer, Irati Ormazabal-Vélez, Joyce Marques de Almeida, Monia Marchetti, Johan Maertens, Marina Machado, Austin Kulasekararaj, José Ángel Hernández-Rivas, Maria Gomes da Silva, Noemí Fernández, Ildefonso Espigado, Ľuboš Drgoňa, Giulia Dragonetti, Elisabetta Metafuni, Maria Calbacho, Ola Blennow, Dominik Wolf, Bjorn van Anrooij, Raquel Nunes Rodrigues, Anna Nordlander, Juan Alberto Martín-González, Raphaël Liévin, Moraima Jiménez, Stefanie K. Gräfe, Ramón García-Sanz, Raúl Córdoba, Laman Rahimli, Tom van Meerten, Oliver A. Cornely, Livio Pagano
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Published in: Clinical Cancer Research
Access to document
10.1158/1078-0432.CCR-22-3136
document
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7. Patients and Methods: Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous antiCD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival...
Jason R. Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B. Miklos, Matthew L. Ulrickson, Miguel Angel Perales, Umar Farooq, Luciano Wannesson, Lori Leslie, Marie José Kersten, Caron A. Jacobson, John M. Pagel, Gerald Wulf, Patrick Johnston, Aaron P. Rapoport, Linqiu Du, Saran VardhanabhutiSimone Filosto, Jina Shah, Julia T. Snider, Paul Cheng, Christina To, Olalekan O. Oluwole, A. Sureda
MO-0960 Evaluating semi-automated 18F-FDG PET segmentation methods to predict Large B-cell lymphoma outcomes
Published in: Radiotherapy and Oncology
Access to document
10.1016/s0167-8140(23)08500-6